Chugai Pharmaceutical Co., Ltd. (TYO:4519)

Market Cap	11.19T
Revenue (ttm)	1.21T
Net Income (ttm)	397.16B
Shares Out	1.65B
EPS (ttm)	241.34
PE Ratio	28.17
Forward PE	24.22
Dividend	100.00 (1.44%)
Ex-Dividend Date	Dec 29, 2025

Volume	4,176,500
Average Volume	3,210,600
Open	6,873.00
Previous Close	6,935.00
Day's Range	6,781.00 - 6,938.00
52-Week Range	5,942.00 - 8,655.00
Beta	0.66
RSI	45.41
Earnings Date	Oct 24, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 re...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,026
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4519

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.